On January 26, 2021 Notable Labs, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, reported that it is hosting a live webinar on February 9th to unveil their integrative data platform (Press release, Notable Labs, JAN 26, 2021, View Source [SID1234574366]). The Notable data scientists will share an in-depth discussion on how data generated from the functional and multi-omic drug sensitivity screen for Acute Myeloid Leukemia (AML) can be harnessed for biomarker discovery, improved drug development and complement patient mutational data for more precise treatment strategies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This webinar will highlight the integration of three technologies: a flow-cytometry drug sensitivity screen, DNA-Seq, and RNA-Seq," said CEO Laurie Heilmann. "By augmenting a stand-alone drug sensitivity screen with multi-omic data, Notable Labs is amassing a continually-growing dataset that ultimately will provide utility for drug development and patient care in AML and other Hematologic oncology indications."

The webinar will cover how this dataset, containing samples with matched drug sensitivity, gene expression, and variant data, enables researchers to look at the relationships between different data types. The data analysis can then be used to discover biomarkers, look at patient population stratification, and gain a deeper understanding of how drug sensitivity is influenced by genetics and gene expression. Advanced registration is required. Please see [link] for complete registration information.